Af­ter fail­ing bad­ly on the new com­mer­cial­iza­tion front, Zealand slash­es US staff, sends off CEO and piv­ots back to R&D

Af­ter dash­ing in­vestors’ hopes last fall on the earn­ing po­ten­tial of the re­cent­ly FDA-ap­proved di­a­betes treat­ment Ze­ga­logue, Zealand Phar­ma is rad­i­cal­ly chang­ing up its game …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER